Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712005 | 0.83 | CYP1A2 (0.34) | DDB1CRBNALDH1A1MAPTMEN1 | |
| SCHEMBL1723265 | 0.81 | CYP1A2 (0.43) | KDM4EDDB1CRBNALDH1A1MAPT | |
| SCHEMBL1711191 | 0.78 | KMT2A (0.36) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15913993 | 0.73 | DDB1 (0.37) | KDM4EDDB1CRBNALDH1A1MAPT | |
| SCHEMBL15913994 | 0.73 | DDB1 (0.37) | KDM4EDDB1CRBNALDH1A1MAPT | |
| SCHEMBL13833230 | 0.73 | DDB1 (0.37) | KDM4EDDB1CRBNALDH1A1MAPT | |
| SCHEMBL1711554 | 0.72 | KMT2A (0.43) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL1723326 | 0.68 | MEN1 (0.39) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1711882 | 0.66 | MEN1 (0.35) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4436893 | 0.64 | HSD17B10 (0.50) | ALDH1A1MAPTHTTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| EP-2344474-B1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| EP-2344474-B1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2009109576-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109576-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | KDM4E 673/4885DDB1 821/4885CRBN 447/4885 |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | KDM4E 1409/4885DDB1 1375/4885CRBN 1241/4885 |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | KDM4E 673/4885DDB1 821/4885CRBN 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.